

## Philippines : Second Health System Enhancement to Address and Limit COVID-19 Under the Asia Pacific Vaccine Access Facility – Additional Financing (HEAL2-AF)

### 1. Project Information

Project ID:	P000555	Instrument ID:	L0555A
Member:	Philippines	Region:	South-Eastern Asia
Sector:	Public Health	Sub-sector:	
Instrument type:	<input checked="" type="checkbox"/> Loan: 250.00 US Dollar million <input type="checkbox"/> Guarantee	Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Department of Finance, Philippines
Implementing Entity:	Department of Health, Philippines		
Project Team Leader:	Wanli Fang (DG: Rajat Misra; Responsible Department: INF1)		
Project Team Members:	Yunlong Liu, OSD - Procurement Specialist; Yogesh Malla, OSD - Financial Management Specialist; Calvin Quek, OSD - Environment & Social Development Specialist; Jinghui Li, Team Member; Lily Jin, Team Member; Bernardita Saez, Project Counsel; Jinghui Li, Project admin;		
Completed Site Visits by AIIB:	Apr, 2022 A joint virtual mission was held during April 10-12 to review the progress of HEAL2 and HEAL2-AF		
Planned Site Visits by AIIB:	Sep, 2022 Joint mission planned for Sep 2022 assuming travel restrictions will be lifted.		
Current Red Flags Assigned:	0		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:			
Previous Red Flags Assigned Date:			

### 2. Project Summary and Objectives

Project objective is to support the Government of the Philippines for procurement of eligible COVID-19 vaccines. This project is proposed to be supported under AIIB's COVID-19 Crisis Recovery Facility and co-financed with the Asian Development Bank (ADB) for the procurement of vaccines eligible under ADB's Asia Pacific Vaccine Access Facility (APVAX) program. The project will provide critically needed vaccines to assist the Government of the Philippines in mitigating adverse health, social, and economic impacts caused by the COVID-19 pandemic.

### 3. Key Dates

Approval:	Dec. 16, 2021	Signing:	Dec. 20, 2021
Effective:	Jan. 27, 2022	Restructured (if any):	
Orig. Closing:	Sep. 30, 2024	Rev. Closing (if any):	

### 4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	0.00
-------------------	--	------------------------	------

Disbursed:	0.00	Most recent disbursement (amount/date):	
Undisbursed:	250.00	Disbursement Ratio (%) <sup>1</sup> :	0.00

**5. Project Implementation Update**

There have been no procurement of vaccines or disbursement of loans under the additional financing project as of end of April 2022.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	None	No non-compliance has been reported	No progress.

**Financial Management:**

The financial management system is effectively being operated. Two DOH finance staff have been assigned to the Project, and a financial management consultant has been retained to support the team. The implementation of the FM Action Plan is progressing well. The Commission on Audit (COA) confirmed that the conduct of the performance audit shall be given priority as soon as audit resources are already available. For the financial audit, the first audited project financial statement is due on June 30, 2022.

**6. Status of the Grievance Redress Mechanism (GRM)**

Project communication with respect to vaccination has commenced. There is no resettlement or land acquisition as part of this Project. The Project will further develop information material containing objectives, activities, timelines, relevant contact information, and a brief summarizing the Project in simple language and infographics targeting wider audience, including the poor and women. The documents will be made available to the public in print and distributed during outreach activities.

**7. Results Monitoring**

No physical progress yet.

**Project Objective Indicators #1**

Number of people vaccinated against COVID-19 (Unit: Million)

Year	Target	Actual	Comments, if any
Sep. 30, 2024	50	N/A	HEAL2 and HEAL2-AF combined. To be reported in 2024

**Intermediate Result Indicators #1**

Vaccine Information Management System (VIMS) launched

Year	Target	Actual	Comments, if any
------	--------	--------	------------------

<sup>1</sup> Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

Dec. 31, 2023	YES	N/A	Department of Information and Communications Technology (DICT) has worked closely with the National Vaccine Operations Center (NVOC) which is tasked to analyze and report on vaccine supply and inoculation through National Covid-19 Vaccine Dashboard. VIMS in its basic format is in operation and is being further developed with more capabilities. Data is being collected from various sites through existing systems. The system is continually updated. A soft launch took place in April 2021.
---------------	-----	-----	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Intermediate Result Indicators #2**

Doses of COVID-19 vaccines procured and delivered to the country (Unit: Million)

Year	Target	Actual	Comments, if any
Sep. 30, 2024	150	N/A	HEAL2 and HEAL2-AF combined. To be reported in 2024

**Intermediate Result Indicators #3**

Gender and socially inclusive protocol and guidelines on the deployment and administration of vaccines, addressing the specific needs of marginalized women and women in especially difficult circumstances, developed, approved, and disseminated.

Year	Target	Actual	Comments, if any
Dec. 31, 2023	Yes	N/A	

**Remarks:**

---